Nuveen Asset Management LLC Has $26.74 Million Stock Position in Henry Schein, Inc. (NASDAQ:HSIC)

Posted by on Mar 2nd, 2023

Nuveen Asset Management LLC reduced its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC – Get Rating) by 5.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 406,562 shares of the company’s stock after selling 23,268 shares during the quarter. Nuveen Asset Management LLC owned 0.30% of Henry Schein worth $26,739,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Cambridge Investment Research Advisors Inc. lifted its position in shares of Henry Schein by 2.4% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 5,262 shares of the company’s stock worth $459,000 after buying an additional 122 shares during the last quarter. Johnson Financial Group Inc. raised its position in Henry Schein by 1.9% in the second quarter. Johnson Financial Group Inc. now owns 7,733 shares of the company’s stock valued at $594,000 after purchasing an additional 147 shares during the last quarter. Wetherby Asset Management Inc. raised its position in shares of Henry Schein by 1.6% during the first quarter. Wetherby Asset Management Inc. now owns 10,860 shares of the company’s stock worth $947,000 after acquiring an additional 171 shares during the last quarter. Sepio Capital LP raised its position in shares of Henry Schein by 2.8% during the third quarter. Sepio Capital LP now owns 6,442 shares of the company’s stock worth $424,000 after acquiring an additional 175 shares during the last quarter. Finally, Daiwa Securities Group Inc. raised its position in shares of Henry Schein by 2.0% during the third quarter. Daiwa Securities Group Inc. now owns 9,052 shares of the company’s stock worth $595,000 after acquiring an additional 180 shares during the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. StockNews.com upgraded Henry Schein from a “hold” rating to a “buy” rating in a research report on Thursday, January 19th. Piper Sandler raised their target price on Henry Schein from $85.00 to $97.00 and gave the stock an “overweight” rating in a research note on Monday, February 6th. Barrington Research decreased their target price on Henry Schein from $99.00 to $92.00 and set an “outperform” rating for the company in a research note on Friday, February 17th. Credit Suisse Group decreased their target price on Henry Schein from $99.00 to $97.00 and set an “outperform” rating for the company in a research note on Tuesday. Finally, Morgan Stanley decreased their target price on Henry Schein from $70.00 to $69.00 and set an “underweight” rating for the company in a research note on Tuesday, February 21st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company. According to MarketBeat, Henry Schein currently has an average rating of “Hold” and an average target price of $85.67.

Insider Activity at Henry Schein

In related news, SVP Lorelei Mcglynn sold 15,341 shares of Henry Schein stock in a transaction that occurred on Tuesday, December 20th. The stock was sold at an average price of $80.70, for a total transaction of $1,238,018.70. Following the transaction, the senior vice president now owns 73,753 shares of the company’s stock, valued at $5,951,867.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO Bradford C. Connett sold 6,840 shares of Henry Schein stock in a transaction on Wednesday, December 21st. The stock was sold at an average price of $80.71, for a total transaction of $552,056.40. Following the sale, the chief executive officer now directly owns 55,412 shares in the company, valued at $4,472,302.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Lorelei Mcglynn sold 15,341 shares of Henry Schein stock in a transaction on Tuesday, December 20th. The stock was sold at an average price of $80.70, for a total value of $1,238,018.70. Following the sale, the senior vice president now owns 73,753 shares in the company, valued at $5,951,867.10. The disclosure for this sale can be found here. Insiders have sold a total of 76,397 shares of company stock valued at $6,190,246 over the last 90 days. Insiders own 1.00% of the company’s stock.

Henry Schein Trading Down 0.7 %

Shares of Henry Schein stock opened at $77.75 on Thursday. The stock has a market capitalization of $10.21 billion, a PE ratio of 19.99, a price-to-earnings-growth ratio of 1.67 and a beta of 0.82. The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.91 and a current ratio of 1.79. Henry Schein, Inc. has a 52 week low of $64.75 and a 52 week high of $92.68. The stock has a 50 day moving average price of $82.58 and a two-hundred day moving average price of $77.07.

Henry Schein (NASDAQ:HSIC – Get Rating) last announced its earnings results on Thursday, February 16th. The company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.21 by $0.14. The company had revenue of $3.37 billion for the quarter, compared to analysts’ expectations of $3.37 billion. Henry Schein had a return on equity of 15.79% and a net margin of 4.25%. Henry Schein’s quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.07 earnings per share. As a group, equities analysts anticipate that Henry Schein, Inc. will post 5.34 earnings per share for the current fiscal year.

About Henry Schein

(Get Rating)

Henry Schein, Inc engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgicals, diagnostic tests, infection-control products and vitamins.

Featured Stories

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.